Treatment of venous thromboembolism with tinzaparin in oncological patients.

Venous thromboembolism (VTE) is a major cause of morbidity and mortality in patients with cancer. For over a decade, the gold standard of treatment and secondary prevention of cancer-associated thrombosis (CAT) has been represented by low-molecular-weight heparins (LMWHs), which are currently recommended as the first-line treatment for CAT. Among the LMWHs that were more extensively tested in patients with CAT, tinzaparin is a LMWH produced by the enzymatic degradation of porcine-derived unfractionated heparin. The efficacy of tinzaparin in this setting is supported by well-grounded evidence. However, there is a need to discuss the positioning of tinzaparin in the continuously evolving treatment scenario of VTE therapy in cancer patients. In this paper, which was developed by a group of clinicians with wide experience in the treatment of VTE in cancer patients, we discuss the current therapeutic options and the role of tinzaparin for the treatment of CAT.

[1]  C. Loprinzi,et al.  Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial , 2020, Journal of thrombosis and haemostasis : JTH.

[2]  F. Scotté,et al.  Treatment and Prevention of Cancer-Associated Thrombosis in Frail Patients: Tailored Management , 2019, Cancers.

[3]  C. Loprinzi,et al.  Apixaban, Dalteparin, in Active Cancer Associated Venous Thromboembolism, the ADAM VTE Trial , 2018, Blood.

[4]  M. Millenson,et al.  NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[5]  E. Clementi,et al.  Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study , 2018, BioDrugs.

[6]  P. Kavan,et al.  Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus. , 2018, Current oncology.

[7]  S. Alzghari,et al.  Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study , 2018, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[8]  G. Raskob,et al.  Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study , 2018, Thrombosis and Haemostasis.

[9]  A. Khorana,et al.  Role of direct oral anticoagulants in the treatment of cancer‐associated venous thromboembolism: guidance from the SSC of the ISTH , 2018, Journal of thrombosis and haemostasis : JTH.

[10]  Lara A. Kahale,et al.  Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. , 2018, The Cochrane database of systematic reviews.

[11]  A. Khorana,et al.  Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study , 2018, Journal of thrombosis and haemostasis : JTH.

[12]  G. Lyman,et al.  Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Khorana,et al.  Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism—Analysis of the CATCH Study , 2018, Thrombosis and Haemostasis.

[14]  C. Rojas-Hernandez.  The role of direct oral anticoagulants in cancer-related venous thromboembolism: a perspective beyond the guidelines , 2018, Supportive Care in Cancer.

[15]  Lara A. Kahale,et al.  Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation. , 2021, The Cochrane database of systematic reviews.

[16]  G. Raskob,et al.  Edoxaban for the Treatment of Cancer‐Associated Venous Thromboembolism , 2017, The New England journal of medicine.

[17]  L. Jara-Palomares,et al.  Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study. , 2017, Thrombosis research.

[18]  P. Gross,et al.  Cancer-Associated Venous Thromboembolism: A Practical Review Beyond Low-Molecular-Weight Heparins , 2017, Front. Med..

[19]  A. Mansfield,et al.  Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer. , 2017, Thrombosis research.

[20]  H. Polo Friz,et al.  The introduction of biosimilars of low molecular weight heparins in Europe: a critical review and reappraisal endorsed by the Italian Society for Haemostasis and Thrombosis (SISET) and the Italian Society for Angiology and Vascular Medicine (SIAPAV) , 2017, Thrombosis Journal.

[21]  M. Perazella,et al.  Acute Kidney Injury in Patients with Cancer. , 2017, The New England journal of medicine.

[22]  A. Khorana,et al.  Tissue Factor As a Predictor of Recurrent Venous Thromboembolism in Malignancy: Biomarker Analyses of the CATCH Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  B. Gyawali.  Biosimilars in oncology: everybody agrees but nobody uses? , 2017, Recenti progressi in medicina.

[24]  S. Mousa,et al.  Tinzaparin for Long-Term Treatment of Venous Thromboembolism in Patients With Cancer: A Systematic Review and Meta-Analysis , 2017, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[25]  A. Cohen,et al.  Cancer-associated venous thromboembolism: Burden, mechanisms, and management , 2016, Thrombosis and Haemostasis.

[26]  J. Douketis,et al.  International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. , 2016, The Lancet. Oncology.

[27]  A. Lamblin,et al.  Low-molecular-weight heparins for cancer-associated thrombosis: Adherence to clinical practice guidelines and patient perception in TROPIQUE, a 409-patient prospective observational study. , 2016, Thrombosis research.

[28]  F. Jen,et al.  A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment , 2016, Journal of Thrombosis and Thrombolysis.

[29]  H. Friz,et al.  Biosimilars of low‐molecular‐weight heparin products: fostering competition or reducing ‘biodiversity’? , 2016, Journal of thrombosis and haemostasis : JTH.

[30]  A. Maraveyas,et al.  Assessing patients’ anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology , 2015, Haematologica.

[31]  Catch Investigators.  Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: A randomized clinical trial , 2015 .

[32]  Gary H Lyman,et al.  Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Agnes Y. Y. Lee,et al.  Prevention and treatment of venous thromboembolism in patients with cancer. , 2014, Hematology. American Society of Hematology. Education Program.

[34]  Elie A Akl,et al.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. , 2012, Chest.

[35]  G. Meyer.  [Secondary prevention of venous thromboembolism in patients with cancer]. , 2011, La Revue du praticien.

[36]  M. Mandalà,et al.  Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  M. Boccadoro,et al.  Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  P. Wells,et al.  Risk of recurrent venous thromboembolism according to malignancy characteristics in patients with cancer-associated thrombosis: a systematic review of observational and intervention studies , 2011, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[39]  Sheridan M. Hoy,et al.  Tinzaparin Sodium , 2010, Drugs.

[40]  S. Mousa,et al.  Anti-cancer properties of low-molecular-weight heparin: Preclinical evidence , 2009, Thrombosis and Haemostasis.

[41]  A. Romera,et al.  A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. , 2009, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[42]  R. White,et al.  Venous Thromboembolism (VTE) in Patients with Cancer: Epidemiology and Risk Factors , 2009, Cancer investigation.

[43]  W. Ageno,et al.  Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry , 2008, Haematologica.

[44]  Russell D Hull,et al.  Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. , 2006, The American journal of medicine.

[45]  H. Chew,et al.  Incidence of venous thromboembolism and its effect on survival among patients with common cancers. , 2006, Archives of internal medicine.

[46]  A. Falanga,et al.  Deep vein thrombosis in cancer: the scale of the problem and approaches to management. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  M. Prins,et al.  Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. , 2003, The New England journal of medicine.

[48]  Yves Gruel,et al.  Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. , 2002, Archives of internal medicine.

[49]  G. Lyman,et al.  Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. , 2019, Thrombosis research.

[50]  R. Descourt,et al.  Tinzaparin and VKA use in patients with cancer associated venous thromboembolism: a retrospective cohort study. , 2015, Thrombosis research.